Asish K. Ghosh, PhD
Asish Ghosh, PhD

The University of Oklahoma Health Sciences Center
Stephenson Cancer Center
975 NE 10th St, BRC North 364
Oklahoma City, OK 73104

PHONE:  405-271-1387

E-MAIL:  asish-ghosh@ouhsc.edu

TITLES

Associate Professor of Medicine

Professional Highlights

  • Fellowships from the Council of Scientific and Industrial Research (CSIR), Government of India – 1990 - 2005
  • Young Investigator Award in 2008 at the Mayo Clinic Angiogenesis Symposium
  • Recipient of the First Hematology Research Summit AWARD at Mayo Clinic - 2012
  • Recipient of the Eagles Cancer Research Award - 2012-2013
  • Member of the ASH Scientific Committee on Lymphoid Neoplasia – 2013
  • Member of the Graduate Program in Biomedical Sciences (GPiBS) Committee, University of Oklahoma: 2016 (3-year term)

Research Interests/Sub-Specialty

  • Extracellular vesicles and tumor microenvironment
  • CLL B cell/bone marrow stromal cell crosstalk
  • Role of extracellular vesicles in CLL progression and therapeutic outcomes
  • CLL B cell biology and drug targeting
  • Receptor tyrosine kinase signaling in CLL B-cells (Pre-/post-therapy)
  • Regulation of leukemic B-cell growth

PUBLICATIONS

Click link for abstract

  1. Boysen J, Nelson M, Magzoub G, Maiti GP, Sinha S, Goswami M, Vesely SK, Shanafelt TD, Kay NE, Ghosh AK. Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression. Leukemia. 2017 Feb; 31(2):350-360. PMID: 27480387.
  2. Kay NE, Sassoon T, Secreto C, Sinha S, Shanafelt TD, Ghosh AK, Arbiser JL. Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2016 Oct; 57(10):2409-16. PMID: 27189785.
  3. Sinha S, Boysen J, Nelson M, Warner SL, Bearss D, Kay NE, Ghosh AK. Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells. Leukemia. 2016 Jun; 30(6):1431-6. PMID: 26598018; PMCID: PMC4879100.
  4. Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE, Ghosh AK. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res. 2015 May 01; 21(9):2115-26. PMID: 25673699; PMCID: PMC4479154.
  5. Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D, Shanafelt TD, Kay NE, Ghosh AK. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia. 2014 Feb; 28(2):451-5. PMID: 24217154; PMCID: PMC3929965.
  6. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. PMID: 23821659; PMCID: PMC3779381.
  7. Ghosh AK, Kay NE. Critical signal transduction pathways in CLL. Adv Exp Med Biol. 2013; 792:215-39. PMID: 24014299; PMCID: PMC3918736.
  8. Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013 Jan 15; 119(2):363-70. PMID: 22760587; PMCID: PMC3902473.
  9. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, Kay NE. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011 Feb 10; 117(6):1928-37. PMID: 21135257; PMCID: PMC3056640.
  10. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Dec; 51(12):2222-9. PMID: 21054149; PMCID: PMC3928074.